/C O R R E C T I O N -- Innovent Biologics/
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2025
0mins
Source: Yahoo Finance
Innovent's Clinical Trial Announcement: Innovent Biologics has successfully dosed the first participant in the Phase 3 clinical trial (GLORY-OSA) of mazdutide, a treatment for moderate-to-severe obstructive sleep apnea and obesity in China, aiming to compare its efficacy against a placebo.
Significance of Mazdutide: This trial is part of ongoing research into mazdutide's potential benefits for managing obesity and metabolic syndromes, addressing a significant unmet medical need in China where no approved treatments for OSA currently exist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
